Open an account

Biostem Technologies

BSEM · OTC

$1.64+$0.10 (+6.49%)TodayMarket closed ·
Prev close $1.54

About BSEM

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The firm's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. The company also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines.

Employees
0
Headquarters
Pompano Beach, Florida
Listed
Jul 11, 2001
Sector
Health Care
Industry
Pharmaceuticals
Website
biostemtechnologies.com

BSEM key statistics

Market cap
30.62M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
146.56K
Volume
163.39K
Open price
$1.58
High today
$1.75
Low today
$1.57
52 Week high
$8.40
52 Week low
$1.45

Biostem Technologies (BSEM) at a glance

Biostem Technologies (BSEM) last traded at $1.64, with a market cap of 30.62M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.57 and $1.75. The current price is 4.5% above the day's low and 6.3% below its high.

Volume so far is 163.39K shares, in line with the average of 146.56K shares a day.

Over the past year Biostem Technologies has ranged from $1.45 to $8.40, and now sits 3% of the way up that range.

Biostem Technologies met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.52 per share against an estimate of -$0.51.

BSEM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 48.0% on average.

  1. Q3 FY24: reported $0.32 per share against an estimate of $0.3672
  2. Q4 FY24: reported $0.74 per share against an estimate of $0.3774
  3. Q4 FY25: reported -$0.01 per share against an estimate of $0.0204
  4. Q1 FY25: reported $0.17 per share against an estimate of $1.27
  5. Q2 FY25: reported -$0.03 per share against an estimate of $0.3264
  6. Q3 FY25: reported $0.03 per share against an estimate of $0.00
  7. Q1 FY26: reported -$0.52 per share against an estimate of -$0.2856
  8. Q2 FY26: reported -$0.52 per share against an estimate of -$0.51

BSEM news

  • Press releasePRNewswire

    BioTissue Holdings, Inc Strengthens Strategic Focus on Ocular Innovation with Sale of Surgical and Wound Care Business to BioStem Technologies

  • Press releaseGlobe Newswire

    BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant

Similar companies

Companies in the same industry as Biostem Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.